The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NVAX | +21.37% | -94.49% | -44% | -87% |
| S&P | +15.57% | +80.16% | +12.49% | +1,014% |
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
The business may not be as strong as its performance this year suggests.
This stock could be a wealth destroyer in the next five years.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $147.14M | 66.6% |
| Gross Profit | $121.94M | 238.3% |
| Gross Margin | 82.87% | 42.1% |
| Market Cap | $1.09B | -15.2% |
| Market Cap / Employee | $1.46M | 0.0% |
| Employees | 749 | -21.3% |
| Net Income | $17.53M | 121.6% |
| EBITDA | $26.15M | 123.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $251.51M | -53.5% |
| Accounts Receivable | $106.45M | -1.7% |
| Inventory | 11.5 | 32.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $265.66M | 7.8% |
| Short Term Debt | $12.39M | -27.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 31.61% | 42.5% |
| Return On Invested Capital | -3140.15% | 28.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$41,551.00K | 76.3% |
| Operating Free Cash Flow | -$39,475.00K | 77.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 2.42 | 2.79 | 4.90 | 2.82 | - |
| Price to Book | -1.65 | -13.49 | 37.37 | -6.97 | 184.91% |
| Price to Sales | 0.91 | 1.03 | 1.32 | 0.99 | -47.69% |
| Price to Tangible Book Value | -1.41 | -5.44 | -18.66 | -4.05 | 105.33% |
| Enterprise Value to EBITDA | 1.19 | 6.38 | -12.15 | 24.56 | -549.16% |
| Total Debt | $228.66M | $228.49M | $251.14M | $278.05M | 5.53% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
